Trials’ results suggest advancements in treatment approaches for CKD/T2D, TIA/minor ischemic stroke, pericarditis and ACS

Investigators in four trials revealed findings to impact treatment of patients with chronic kidney disease/Type 2 diabetes, TIA or minor ischemic stroke, pericarditis and ACS during their Late-Breaking Science session “Randomized Trials: Brain, Kidney and Heart” on Monday.

COVID-19 cardiovascular disease registry documents relationships between CVD and COVID-19

Researchers for “AHA Goes Viral: COVID-19, Influenza Vaccines and Cardiovascular Disease,” Late-Breaking Sessions on Tuesday reported:

  • Nationwide COVID-19 cardiovascular disease registry details cardiovascular complications.

Clinical trials that are making strides in digital interventions to improve CV patient care

Investigators in four trials shared creative and effective approaches for optimizing patient health at the Late-Breaking Scientific session “High Tech or High Touch: Creative Strategies to Optimize Patient Care” on Tuesday.

Heart failure and atrial fibrillation: Vitamins, minerals, nutrients and more

Investigators revealed surprising findings about supplemental iron, omega-3 fatty acids and vitamin D3 during their Late-Breaking Science session “Heart Failure and Atrial Fibrillation: Vitamins, Minerals, Nutrients and More” on Friday. Their findings include:

  • Omecamtiv mecarbil, a novel cardiac myotrope, may help manage patients with heart failure.

Cost, access, adherence key challenges in global CVD prevention

Researchers in the “Bending the Curve for CVD: Precision or PolyPill?” Late-Breaking Science session on Friday found:

  • More affordable, effective and accessible primary prevention is needed to reduce the burden of global cardiovascular disease.

Clinical trials provide insights into CVD diagnosis in women, treatment for PCI and arrhythmia-associated bioprosthetic mitral valves

In Saturday’s Late-Breaking Science session, “Current Challenges in Coronary and Valve Disease,” three cardiac investigators revealed compelling data on alternative medications and multimodal imaging for patients in niche groups:

Trials shed light on fish oil, statin side effects and a new pathway to manage lipids

Investigators in four trials revealed compelling clinical science contributing to the story of lipid therapy on cardiovascular disease prevention during “Fish Oil, Fancy Drugs and Frustrations in Lipid Management” Late-Breaking Science session on Sunday.

The latest clinical trial results in managing thrombosis in stents

Researchers in Sunday’s “Stents, Valves and Clots” Late-Breaking Science session revealed:

  • Drug-eluting stents with rapid polymer degradation are not inferior to standard polymer DES.
  • One-month dual anti-platelet therapy is not inferior to recommended therapy following DES.

AF trials reveal pragmatic screening and intervention opportunities

Investigators in four atrial fibrillation trials revealed compelling results during Monday’s “To Screen or Not to Screen, and Then What? Studies of Detection and Treatment of AF” Late-Breaking Science session.

Thank you for helping to make #AHA20 a resounding success

Thank you for joining us for the Scientific Sessions and ReSS 2020 virtual experience. Even though we couldn’t meet in person this year, you joined us from your offices and homes to help make it a resounding success.